...PHOENIX Ariz. June 5 2013 Dr. Matt Huentelman of the Translational...They will be honored at an awards ceremony June 27 at the Phoenix Art ...Dr. Huentelman Ph.D. is an Associate Professor in TGen's Neurogenomi...Dr. Huentelman also is the Co-Director of TGen's Center for Rare Child...

PHOENIX, Ariz. June 5, 2013 Dr. Matt Huentelman of the Translational Genomics Research Institute (TGen) and Dr. Glen Weiss of TGen and Cancer Treatment Centers of America (CTCA) are among the 40 business leaders under 40 years of age named by the Phoenix Business Journal to its 13th Annual Class of 40 Under 40.

They will be honored at an awards ceremony June 27 at the Phoenix Art Museum.

Dr. Huentelman, Ph.D., is an Associate Professor in TGen's Neurogenomics Division, where he oversees research programs focused on sensory disorders, including hearing and vision loss, and on aging and age-related diseases, such as Alzheimer's disease and the genetics of learning and memory highlighted recently by the launch of TGen's MindCrowd project (http://www.MindCrowd.org).

Dr. Huentelman also is the Co-Director of TGen's Center for Rare Childhood Disorders, which investigates uncommon neurologic problems among children, often those that are only a collection of symptoms with no diagnosis.

"I am honored to be selected among the 40 Under 40 by the Phoenix Business Journal," Dr. Huentelman said. "This recognition serves to highlight the significant advances that TGen has made through the study of the human genome, and the insights and breakthroughs being made, not only by me, but by our entire scientific staff every day."

Dr. Weiss, M.D., is a Clinical Associate Professor in TGen's Cancer and Cell Biology Division and is Director of Clinical Research at CTCA. His research focuses on genomic and other 'omics characterizations of lung cancer, rare cancers and early-detection strategies.

Dr. Weiss has been selected by CTCA at Western Regional Medical Center to head the startup of a new clinical research program in Goodyear, Ariz. Dr. Weiss is also Co-Unit Head of TGen's Lung Cancer Research Laboratory.

"As a research scientist, being a member of the 40 Under 40 is a reflection of the collaborations I am privileged to conduct through TGen and CTCA," Dr. Weiss said. "As a medical doctor, these collaborations lead to new therapies that can help the patients that look to us for healing and hope."

The 40 Under 40 program's hundreds of alumni includes Phoenix Mayor Greg Stanton, a member of the TGen Board of Directors, and Arizona Diamondbacks President Derrick Hall, a member of TGen's National Advisory Council for Pancreatic Cancer Research.

(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...

(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...

(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...

(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...